Clinical Trials

12 enrolled

Phase 3 Not yet recruiting

Carcinoma, Neuroendocrine

NCT06822751 2026-02-17

FOMUTI

138 enrolled

Cystitis, Prostatitis, Urinary Tract Infections, Multiple Endocrine Neoplasia Type 1

NCT07376837 2026-01-29

PTC-RFA

30 enrolled

Thyroid Cancer, Papillary

NCT07373015 2026-01-28

Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm

EndocrineGastrointestinalNET

118 enrolled

Rectal Neuroendocrine Tumors

NCT07366658 2026-01-26

NEUK203-13

9 enrolled

Phase 4 Not yet recruiting

Neuroendocrine Tumors

NCT07354698 2026-01-21

MHI

114 enrolled

Thyroid Cancer, Papillary

NCT07337447 2026-01-13

REWENEC 01

122 enrolled

Carcinoma, Neuroendocrine

NCT07316101 2026-01-05

Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery

20 enrolled

CNSEndocrine

Craniopharyngioma, Pituitary Neoplasms

NCT07274657 2025-12-10

SMILE

EndocrineGastrointestinalNETOther solid neoplasm

150 enrolled

Pancreas Adenocarcinoma (MSI-H)

NCT07252661 2025-11-28

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

DermatologicEndocrineGastrointestinalGenitourinaryHead & Neck

40 enrolled

Thyroid cancer, medullary, Carcinoma, Renal Cell, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis

NCT07165132 2025-09-10

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

EndocrineGastrointestinalNET

104 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07156019 2025-09-04

Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma

32 enrolled

Carcinoma, Neuroendocrine

NCT07141147 2025-09-03

A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery.

58 enrolled

Adrenocortical Carcinoma

NCT07014254 2025-06-10

Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies

20 enrolled

Neuroendocrine Tumors

NCT06730893 2025-04-30

MAeSTro-SDM

310 enrolled

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT06951243 2025-04-30

A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer

40 enrolled

Advanced Extrapulmonary Neuroendocrine Cancer

NCT06936735 2025-04-20

Phase I Study of HS-20108 in Participants With Advanced Solid Tumors

502 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT06901856 2025-03-30

Endoscopic Resection for Small Rectal Neuroendocrine Tumors

EndocrineGastrointestinalNET

120 enrolled

Rectal Neuroendocrine Tumor

NCT06899347 2025-03-27

PRO-COMAND

196 enrolled

Thyroid Cancer, Papillary

NCT06816394 2025-02-10

TAURUS

32 enrolled

Carcinoma, Neuroendocrine

NCT06804863 2025-02-03

Regret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer

600 enrolled

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT06764368 2025-01-08

Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors

39 enrolled

Neuroendocrine Tumors

NCT06713304 2024-12-16

A Community-Based Intervention to Reduce Alcohol Use in Vietnamese Men

104 enrolled

Alcohol Drinking, Multiple Endocrine Neoplasia Type 1

NCT06556186 2024-08-15

Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma

600 enrolled

Pituitary Neoplasms

NCT04889742 2023-12-26

HETERERO

EndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

110 enrolled

Hyperthermia, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fever, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Neuroendocrine Tumors

NCT06156332 2023-12-05

A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy

EndocrineOther solid neoplasm

39 enrolled

Advanced Solid Tumors With Neuroendocrine Differentiation

NCT05894486 2023-06-08

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

40 enrolled